Wei Xiao, Chen Fangjun, Xin Kai, Wang Qin, Yu Lixia, Liu Baorui, Liu Qin
The Comprehensive Cancer Center of Drum Tower Hospital, Nanjing Medical University.
The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University.
Transl Oncol. 2019 May;12(5):733-738. doi: 10.1016/j.tranon.2019.02.008. Epub 2019 Mar 14.
Cancer vaccines, including peptide-based vaccines, have been considered a key tool of effective and protective cancer immunotherapy because of their capacity to provide long-term clinical benefit for tumors. Among a large number of explorations of peptide antigen-based vaccines, cancer-testis antigens (CTAs), which are activated in cancers but silenced in normal tissues (except testis tissue), are considered as ideal targets. Currently, personalized treatment for cancer has become a trend due to its superior clinical efficacy. Thus, we envisage rational selection of CTA peptides to design "personalized" CTA peptide vaccines. This review summarizes the advances in CTA peptide vaccine research and discusses the feasibility of establishing "personalized" CTA peptide vaccines.
癌症疫苗，包括基于肽的疫苗，因其能够为肿瘤提供长期临床益处，而被视为有效且具有保护性的癌症免疫疗法的关键工具。在大量基于肽抗原的疫苗探索中，癌症睾丸抗原（CTAs）在癌症中被激活但在正常组织（睾丸组织除外）中沉默，被认为是理想的靶点。目前，癌症的个性化治疗因其卓越的临床疗效已成为一种趋势。因此，我们设想合理选择CTA肽来设计“个性化”CTA肽疫苗。本综述总结了CTA肽疫苗研究的进展，并讨论了建立“个性化”CTA肽疫苗的可行性。
